![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Osaka Prefectural Institute of Public Health (H.Y., K.I., T.S.) and Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine (C.G.T., F.P.G.)
 |
Abstract |
|---|
Abstract
Introduction
Results
Discussion
References
|
|---|
Effects of freezing, thawing, and storage at room temperature of
human liver samples on the contents and catalytic activities of
individual forms of cytochrome P450 (P450 or CYP) were examined. The
stability of liver genomic DNA was also investigated. There were no
significant decreases in microsomal levels or catalytic activities of
P450 enzymes by storage at 
80°C for 5 years. We then examined the
effects of freezing/thawing of liver samples. Levels of P450 forms were
determined immunochemically and by the activities of typical drug
oxidation reactions in liver microsomes of human samples, which were
divided into two groups. One group of samples was thawed and kept at
25°C for 6 hr and then frozen again and kept for 1 week at 80°C.
In the other group, liver microsomes were prepared at the same time (as
those from the other group), but not thawed and refrozen. Thawing the
liver samples and storage for 6 hr at 25°C decreased contents of
total P450 by about 90% and activities of both NADH-ferricyanide and
NADPH-cytochrome c reductases by about 80%. However, the
decrease in b5 levels was only about
30%. Spectral studies of P450 suggested that thawing the liver samples
and holding them at 25°C produced inactive form P420. P450 proteins
were detected by immunoblot analysis with or without thawing, but
catalytic activities for individual P450s were decreased drastically by
thawing and holding samples for 6 hr at 25°C. Only 10% of
tolbutamide methyl hydroxylation activity was present, and there was no
detectable ethoxyresorufin O-deethylation activity in such
microsomes after thawing and holding samples for 6 hr at 25°C.
Genomic DNA from human livers was also found to be degraded after the
samples were thawing. These results suggested that thawing and holding
the liver samples at 25°C decreased the levels and activities of
P450s in microsomes and that there are differences in stabilities in
individual forms of P450 proteins. P450 proteins determined
immunochemically do not always reflect P450-catalytic functions in
human liver microsomes because of difficulties in obtaining fresh liver
samples.
| |
Introduction |
|---|
Abstract
Introduction
Results
Discussion
References
|
|---|
Liver microsomal drug-metabolizing enzymes contribute significantly to the biotransformation of xenobiotic chemicals such as drugs, toxic chemicals, and carcinogens as well as of endobiotic chemicals including steroids, fatty acids, prostaglandins, and vitamins (1, 2). Among various liver enzymes examined, P450 is most important in determining pharmacokinetic and toxicokinetic properties of drugs (3, 4). P450 comprises a superfamily of the enzymes (5), and the catalytic roles of P450 enzymes in the same gene families have been suggested to be generally similar among animal species examined (6, 7). However, recent studies have indicated numerous cases in which species-related differences exist in the expression and catalytic roles of individual forms of P450 in experimental animals and humans, and it is important to identify which human P450 enzymes contribute to the oxidation of drugs to define the safety of clinically used drugs (8, 9).
Roles of human P450 enzymes in the oxidation of a variety of xenobiotic chemicals have been determined recently, using recombinant P450 proteins in the chimeric organisms into which respective human P450 cDNAs had been introduced (10-13). However, caveats must be taken if two or more P450 enzymes are involved in (i) oxidation at the same site of a drug substrate with different affinities or (ii) at the different sites of drug molecules forming different metabolites (14-17). Use of human liver microsomes is, therefore, of great use in characterizing drug oxidation reactions catalyzed by different forms of P450 (3, 18). Owing to the difficulties in obtaining fresh liver samples, investigators are studying human P450 research using surgical liver samples or liver tissues from organ donors (18). However, only limited information is available as to whether each of the P450 forms in human livers degrade at the same rates when human samples were kept for few hours without freezing or were stored for long time in freezer (19).
In this study, we examined the effects of freezing and thawing of human
liver samples and handling them at room temperature on the contents and
catalytic activities of individual forms of P450. Two types of
experiments were carried out. One of the experiments was designed to
see if the microsomal P450 enzymes are degraded when human liver
samples were kept at 80°C for long time (5 years). The other
experiments were carried out to compare the stabilities of individual
forms of P450 when frozen human liver samples were thawed and kept at
room temperature (25°C) for 6 hr. The 6 hr at 25°C conditions was
selected to approximate conditions in which surgical and organ donor
samples are not properly handled before freezing for long term storage.
Materials and Methods
Chemicals. Coumarin, tolbutamide, and ethoxyresorufin were purchased from Sigma Chemical Co. (St. Louis, MO). Other drug substrates, their metabolites, and reagents used in this study were obtained from sources as described previously or of highest qualities commercially available (14, 18, 20-22).
Enzyme Preparation.
Human liver samples were obtained from organ donors as described
previously (18, 21). These samples were removed within 20 min of death,
placed in ice cold 1.15% KCl (w/v), and packed in for delivery to the
laboratory, at which time the samples were cut into small pieces (ca.
5-10 cm3), frozen by immersion in liquid nitrogen, and
stored in small aliquots at 80°C (19, 23). Liver microsomes were
prepared as described and suspended in 10 mM Tris-Cl buffer (pH 7.4)
containing 1.0 mM EDTA and 20% glycerol (v/v) (24).
Freezing/Thawing of Human Liver Samples.
Effects of freezing and thawing of human liver samples and holding at
room temperature on the contents and catalytic activities of individual
forms of cytochrome P450 were examined. The experiments were carried
out by comparing the levels of P450 forms determined immunochemically
and the activities of typical drug oxidation reactions in liver
microsomes of human samples that were divided into two groups. One
group of liver samples was thawed and kept at room temperature (25°C)
for 6 hr and then refrozen (for 1 week at 80°C). Liver microsomes
of these samples were prepared at the same time as those of the other
group, which were not thawed and refrozen.
Enzyme Assays. Liver microsomal incubations included microsomes (0.5 mg protein/ml) in 100 mM potassium phosphate buffer (pH 7.4) containing an NADPH-generating system consisting of 0.5 mM NADP+, 5 mM glucose 6-phosphate, and 0.5 unit of glucose 6-phosphate dehydrogenase/ml, and various concentrations of drug substrates (18, 20, 31). For the assay of nifedipine oxidation activities, 30 mM MgCl2 was included and the buffer was replaced by 50 mM potassium HEPES buffer (pH 7.4)(32, 33).
Activities of ethoxyresorufin O-deethylation (substrate concentration of 10 µM) and coumarin 7-hydroxylation (50 µM) were assayed fluorometrically according to the methods as described (24, 34, 35). Methyl hydroxylation of tolbutamide (substrate concentration of 2.5 mM) and 4
-hydroxylation of mephenytoin (0.4 mM) were determined
using high-performance liquid chromatography as described (18, 28, 36,
37). The methods used for bufuralol 1-hydroxylation (substrate
concentration, 0.2 mM), chlorzoxazone 6-hydroxylation (0.5 mM), and
nifedipine oxidation (0.2 mM) were described previously (14, 22, 27,
38).
P450 and b5 were estimated spectrally by the
methods of Omura and Sato (39). NADH-ferricyanide and NADPH-cytochrome
c reductase activities were determined by the methods
described (40-42). The contents of human P450 proteins in liver
microsomes were estimated by coupled sodium dodecyl
sulfate-polyacrylamide gel electrophoresis/immunochemical development
("Western-blotting") (43). The intensities of the immunoblots were
measured with an Epson GT-8000 Scanner equipped with NIH Image/Gel
Analysis Program adapted for Macintosh computers. Protein
concentrations were estimated by the method of Lowry et al.
(44).
Electrophoretic Analysis of Genomic DNA of Human Livers.
Genomic DNA of human liver samples was analyzed on a 1% agarose (w/v)
gel electrophoresis. In some experiments, exon 3 of CYP2C9
was amplified using the forward primer 5-GGATATGAAGCAGTGAAGGAA-3 and
the reverse primer 5-GGCCTTGGTTTTTCTCAACTC-3 (45). Genomic DNA (25 ng) was amplified for 35 cycles with a Perkin Elmer thermocycler (Gene
Amp PCR System 2400) using conditions recommended by the manufacture.
Amplification was performed with cycles of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 2 min.
An initial denaturation at 94°C for 5 min and a final extension at
72°C for 10 min were also performed. The PCR products were analyzed
on 10% polyacrylamide gel electrophoresis.
Statistical Analysis. Statistical analysis was analyzed by Student's t-test.
| |
Results |
|---|
|
Abstract
Introduction
Results
Discussion
References
|
|---|
Effects of Storage of Human Liver Samples on the P450 Contents and
Activities in Microsomal Fractions.
Frozen liver samples from six organ donors were divided into two
groups. One group of samples was used to prepare liver microsomes one
month later after freezing the livers at 80°C, and the microsomes thus obtained were stored at 80°C for 5 years. Other group of liver
samples was kept at 80°C for 5 years and then liver microsomes were
prepared. P450 contents and P450-dependent drug oxidation activities in
liver microsomes of both groups were determined and compared (table
1). Total P450 contents determined spectrally were not
different in the two groups; the relative levels of P450 and P420 by
spectral analysis were essentially the same in both groups (results not
shown). We also determined P450-dependent drug oxidation activities
with the substrates ethoxyresorufin, coumarin, tolbutamide,
mephenytoin, bufuralol, chlorzoxazone, and nifedipine (shown to be
prototypic substrates for CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4,
respectively, in human liver microsomes (3, 7, 18, 46)). There were no
significant differences in liver microsomal drug oxidation activities
between the two groups.
|
Effects of Thawing of Liver Samples on the Contents and Catalytic
Activities of P450 in Microsomal Fractions.
Liver samples from six organ donors were divided into two groups. One
group of liver samples was thawed and kept at room temperature (25°C)
for 6 hr and then frozen again and kept at 80°C for 1 week. This
treatment was selected to reflect poor conditions for determining
samples prior to long term storage. Other samples were kept at 80°C
without thawing. Liver microsomes of these samples were prepared at the
same time as those from the other group, which were not thawed and
refrozen.
|
|
|
Stabilities of Individual Forms of P450 in Microsomal Fractions of Six Human Livers. Microsomes (12 µg of protein) from 6 human livers were subjected to SDS-polyacrylamide gel electrophoresis, with or without thawing and storage at 25°C for 6 hr, and the P450 proteins were detected immunochemically using antibodies raised against CYP1A2, 2A6, 2C9, 2D1, 2E1, and 3A4 on immunoblotting analysis. Levels of individual P450 enzymes were determined using purified CYP2A6, 2C9, 2E1, and 3A4 enzymes and the recombinant CYP1A2 and 2D6 as standards. About 70% of the P450 was recovered immunochemically in liver microsomes of individual human subjects, and it was also found that there was good correlation between spectrally determined P450 and sum of the immunochemically determined P450s in microsomes of 6 human livers with and without thawing and storage at 25°C for 6 h (r = 0.92). However, it should be mentioned that in some samples (particularly sample HL-6), P450 proteins determined immunochemically were calculated higher than those determined spectrally (see below).
Levels of individual forms of P450 in microsomes of six human livers with or without thawing and storage at 25°C for 6 hr were compared (fig. 3). There were decreases in levels of individual forms of P450 in microsomal fractions after the livers were thawed and kept at 25°C for 6 hr, and the extent of P450 degradation was different with human samples and individual P450 forms examined. For example, decreases in P450 proteins were very notable in human sample HL-2 as compared with those in other human samples. Also, the sum of the contents of individual P450 proteins determined immunochemically in microsomes of sample HL-6, whose livers were kept at 25°C for 6 hr, were about 3-fold higher than the contents of total P450 determined spectrally. Samples HL-6 and HL-11 contained mainly CYP3A4 and 2E1, respectively, in liver microsomes, and these P450s were present at relatively high levels in immunoblotting analysis after the samples were thawed and kept at 25°C for 6 hr.
|
|
|
-hydroxylation (CYP2D6, r = 0.88), chlorzoxazone
6-hydroxylation (CYP2E1, r = 0.73), and nifedipine
oxidation (CYP3A4, r = 0.82).
Effects of thawing of liver samples and standing at room temperature on genomic DNA and amplified DNA products with CYP2C9 DNA probe. Genomic DNA of six human liver samples was also degraded after the samples were thawing and stored at 25°C for 6 hr when analyzed by agarose gel electrophoresis (figs. 5A and 5B). The absorbance ratio of 260 nm and 280 nm was essentially the same in genomic DNA isolated from liver samples with or without thawing and standing the samples at 25°C for 6 hr (results not shown). We also determined the amplified products of genomic DNA probed with primers of exon 3 of the CYP2C9 gene using polyacrylamide gel electrophoresis (Figs. 5C and 5D). The results showed that the product with same molecular weight (420 bp) was detected in samples with thawing and holding at 25°C for 6 hr, while the intensities of the bands were weaker.
| |
Discussion |
|---|
|
Abstract
Introduction
Results
Discussion
References
|
|---|
In this study the effects of storage and freezing/thawing/storage
at room temperature of human liver samples on the contents and
catalytic activities of individual forms of P450 were examined. Our
results indicate that storage of human liver samples at 80°C for 5 years does not affect significantly the contents of P450 and activities
of P450-dependent drug oxidations in microsomes when compared with
microsomes of the same human livers to which liver microsomes were
first isolated and stored at 80°C for about 5 years. Powis et
al. (47) have also reported that there are no significant
decreases in contents of P450 and activities of biphenyl
4-hydroxylation and halothane reduction when liver microsomes, liver
homogenates, or small pieces of liver samples were stored in deep
freezer for 1 month, 6 months, and 12 months. P450-dependent drug
oxidation activities are reported to be very stable in liver microsomes
when the microsomes are suspended in buffers containing 20% glycerol
(24, 48).
We then examined the effects of freezing/thawing of liver samples on the microsomal contents and activities of individual forms of P450. Thawing the liver samples and holding them at 25°C for 6 hr decreased contents of total P450 by about 90% and activities of both NADH-ferricyanide and NADPH-cytochrome c reductases by about 80%. However, the decrease in b5 levels was only about 30% when the hemoprotein was determined with sodium dithionite as a reducing equivalent. When NADH was used for the determination of b5 in microsomes with thawing the livers, no spectral changes were observed, indicating that electrons were probably not supplied as efficiently due to inactivation of NADH-b5 reductase. These results suggest that among microsomal electron transfer proteins, b5 is relatively stable to degradation. It is interesting in this connection to note that there are different rates of biological half lives in the membrane-bound proteins in liver microsomes and that among various membrane proteins examined b5 has longer half lives than P450 enzymes and NADPH-P450 reductase in rat liver microsomes (49, 50).
Spectral determination of P450 suggested that thawing and standing the liver samples at 25°C for 6 hr produced the inactive form, P420, in microsomes. The degradation of P450 to P420 caused decreases in drug oxidation activities by liver microsomes. The decreases in levels and activities of individual forms of P450 in microsomal fractions varied with human samples and individual P450 forms examined. For example, decreases in P450 proteins in a human sample HL-2 were very notable when compared with those in other human samples. In contrast, the sum of the contents of individual P450 proteins determined immunochemically in a human sample HL-6 was significantly (about 3-fold) higher than those of total P450 determined spectrally when livers were thawed and kept at 25°C for 6 hr. These results suggest that the extents of P450 degradation are not always the same in different human samples examined, and that the levels of P450 proteins detected immunochemically do not always match those of active P450 proteins.
Despite the fact that several P450 proteins were detected on
immunoblotting analysis with large interindividual variations in
samples with or without thawing and storage at 25°C for 6 hr, catalytic activities for individual P450 enzymes were decreased drastically by the procedure. Among the P450-catalyzed reactions examined, tolbutamide methyl hydroxylation was more stable (but still
dropped to 10%), while ethoxyresorufin O-deethylation
activity was very sensitive in microsomes when livers were thawed and
stored at 25°C for 6 hr. Coumarin 7-hydroxylation activities were
also detected in microsomes of livers with thawing/holding at 25°C for 6 hr, and these activities were somewhat correlated with the levels
of CYP2A6 determined immunochemically with some exception. Such
relations in activities and contents of P450s were also observed with
bufuralol 1-hydroxylation and CYP2D6, chlorzoxazone 6-hydroxylation and CYP2E1, and nifedipine oxidation and CYP3A4. The different stabilities among individual P450 enzymes examined may be a result of
the different susceptibilities of these P450 enzymes against proteolytic damage by intracellular proteases.
Agarose gel-electrophoresis of genomic DNA isolated from six human liver samples suggested that thawing/freezing and storage the livers at 25°C for 6 hr caused degradation of DNA. However, analysis with polyacrylamide gel-electrophoresis of the PCR products amplified with primers of CYP2C9 cDNA in these DNA samples suggested that small fragments of degraded DNA were retained in the DNA fractions.
In conclusion, there were no significant decreases in microsomal levels
and catalytic activities of P450 enzymes when liver samples were kept
at 80°C for 5 years. The results suggest that thawing of freezed
liver samples and stored at 25°C for 6 hr decreased the levels and
activities of P450s in microsomes and that there are differences in
stabilities in individual forms of P450 proteins. The 6 hr at 25°C
conditions was selected to approximate conditions in which surgical and
organ donor samples are not properly handled before freezing for long
term storage. Our results also suggested that P450 proteins determined
immunochemically do not always show P450-catalytic functions in human
liver microsomes because of difficulties in obtaining fresh liver
samples.
| |
Note added in proof |
|---|
After completing to write this manuscript, we became aware of a paper of Pearce et al. (51) who reported their studies on the effects of freezing, thawing, and storing human liver microsomes. However, it should be mentioned that the present paper deals with freezing, thawing, and storage of human liver samples on the effects of P450 contents and catalytic activities in liver microsomes.
| |
Footnotes |
|---|
Received August 26, 1996; accepted October 18, 1996.
This work was supported in part by Grants from the Ministry of Education, Science, and Culture of Japan, the Ministry of Health and Welfare of Japan, and the Developmental and Creative Studies from Osaka Prefectural Government, and by United States Public Health Service Grants CA44353 and ES00267.
Send reprint requests to: Dr. T. Shimada, Osaka Prefectural Institute of Public Health, 3-69 Nakamichi 1-chome, Higashinari-ku, Osaka 537, Japan.
| |
Abbreviations |
|---|
Abbreviations used are: P450 or CYP, cytochrome P450; P420, cytochrome P420; b5, cytochrome b5; SDS, sodium dodecyl sulfate.
| |
References |
|---|
|
Abstract
Introduction
Results
Discussion
References
|
|---|
| 1. | F. J. Gonzalez: The molecular biology of cytochrome P450s. Pharmacol. Rev. 40, 243-288 (1989)[Medline]. |
| 2. |
F. P. Guengerich:
Reactions and significance of cytochrome P-450 enzymes.
J. Biol. Chem.
266,
10019-10022 (1991) |
| 3. | F. P. Guengerich and T. Shimada: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4, 391-407 (1991)[Medline]. |
| 4. | F. J. Gonzalez, T. Aoyama, and H. V. Gelboin: Activation of promutagens by human cDNA-expressed cytochrome P450s. In "Mutation and the Environment, Part B: Metabolism, Testing Methods, and Chromosomes" (M.L. Mendelshon and R.J. Albertini, eds.), pp. 77-86. Wiley Liss, New York, 1990. |
| 5. | D. R. Nelson, L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, and D. W. Nebert: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42 (1996)[Medline]. |
| 6. | D. W. Nebert, D. R. Nelson, M. Adesnik, M. J. Coon, R. W. Estabrook, F. J. Gonzalez, F. P. Guengerich, I. C. Gunsalus, E. F. Johnson, B. Kemper, W. Levin, I. R. Phillips, R. Sato, and M. Waterman: The P450 superfamily: update listing of all genes and recommended nomenclature for the chromosomal loci. DNA 8, 1-13 (1989)[Medline]. |
| 7. | D. E. Ryan and W. Levin: Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol. Ther. 45, 153-239 (1990)[Medline]. |
| 8. | S. A. Wrighton, B. J. Ring, and M. Vandenbranden: The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol. Pathol. 23, 199-208 (1995)[Medline]. |
| 9. | F. P. Guengerich: Human cytochrome P450 enzymes. In "Cytochrome P450" (P.R. Oritiz de Montellano, ed.), pp. 473-535. Plenum Press, New York, 1995. |
| 10. | F. P. Guengerich, W. R. Brian, M. A. Sari, and J. T. Ross: Expression of mammalian cytochrome P-450 enzymes using yeast-based vectors. Methods Enzymol. 206, 130-145 (1991)[Medline]. |
| 11. |
C. L. Crespi,
B. W. Penman,
D. T. Steimel,
H. V. Gelboin, and
F. J. Gonzalez:
The development of a human cell line stably expressing human CYP3A4: role in the metabolic activation of aflatoxin B1 and comparison to CYP1A2 and CYP2A3.
Carcinogenesis
12,
355-359 (1991) |
| 12. | C. Wolfel, B. Heinrich-Hirsch, T. Schulz-Schalge, A. Seidel, H. Frank, U. Ramp, F. Wachter, F. J. Wiebel, F. Gonzalez, H. Greim, and J. Doehmer: Genetically engineered V79 chinese hamster cells for stable expression of human cytochrome P450IA2. Eur. J. Pharmacol. 228, 95-102 (1992)[Medline]. |
| 13. | J. Buters, K. R. Korzekwa, K. L. Kunze, Y. Omata, J. P. Hardwick, and F. J. Gonzalez: cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab. Dispos. 22, 688-692 (1994)[Abstract]. |
| 14. | H. Yamazaki, Z. Guo, M. Persmark, M. Mimura, K. Inoue, F. P. Guengerich, and T. Shimada: Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol. Pharmacol. 46, 568-577 (1994)[Abstract]. |
| 15. | H. Yamazaki, K. Inoue, M. Mimura, Y. Oda, F. P. Guengerich, and T. Shimada: 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem. Pharmacol. 51, 313-319 (1996)[Medline]. |
| 16. | R. Kato and Y. Yamazoe: The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 4, 359-362 (1994)[Medline]. |
| 17. | T. Yasumori, K. Nagata, S. K. Yang, L. S. Chen, N. Murayama, Y. Yamazoe, and R. Kato: Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 3, 291-301 (1993)[Medline]. |
| 18. |
T. Shimada,
H. Yamazaki,
M. Mimura,
Y. Inui, and
F. P. Guengerich:
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians.
J. Pharmacol. Exp. Ther.
270,
414-423 (1994) |
| 19. | P. Wang, P. S. Mason, and F. P. Guengerich: Purification of human liver cytochrome P-450 and comparison to the enzyme isolated from rat liver. Arch. Biochem. Biophys. 199, 206-219 (1980)[Medline]. |
| 20. |
T. Shimada,
M. Iwasaki,
M. V. Martin, and
F. P. Guengerich:
Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002.
Cancer Res.
49,
3218-3228 (1989) |
| 21. | M. Mimura, T. Baba, H. Yamazaki, S. Ohmori, Y. Inui, F. J. Gonzalez, F. P. Guengerich, and T. Shimada: Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metab. Dispos. 21, 1048-1056 (1993)[Abstract]. |
| 22. | R. Peter, R. Böcker, P. H. Beaune, M. Iwasaki, F. P. Guengerich, and C. S. Yang: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem. Res. Toxicol. 3, 566-573 (1990)[Medline]. |
| 23. | P. P. Wang, P. Beaune, L. S. Kaminsky, G. A. Dannan, F. F. Kadlubar, D. Larrey, and F. P. Guengerich: Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22, 5375-5383 (1983)[Medline]. |
| 24. | F. P. Guengerich: Analysis and characterization of enzymes. In "Principles and Methods of Toxicology" (A. W. Hayes, ed.), pp. 1259-1313. Raven Press, New York, 1994. |
| 25. | P. Sandhu, Z. Guo, T. Baba, M. V. Martin, R. H. Tukey, and F. P. Guengerich: Expression of modified human cytochrome P450 1A2 in Escherichia coli. Stabilization, purification, spectral characterization, and catalytic activities of the enzymes. Arch. Biochem. Biophys. 309, 168-177 (1994)[Medline]. |
| 26. | C. H. Yun, T. Shimada, and F. P. Guengerich: Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. 40, 679-685 (1991)[Abstract]. |
| 27. |
F. P. Guengerich,
M. V. Martin,
P. H. Beaune,
P. Kremers,
T. Wolff, and
D. J. Waxman:
Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.
J. Biol. Chem.
261,
5051-5060 (1986) |
| 28. |
T. Shimada,
K. S. Misono, and
F. P. Guengerich:
Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction.
J. Biol. Chem.
261,
909-921 (1986) |
| 29. | F. P. Guengerich, D. H. Kim, and M. Iwasaki: Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179 (1991)[Medline]. |
| 30. | L. S. Kaminsky, M. J. Fasco, and F. P. Guengerich: Production and application of antibodies to rat liver cytochrome P-450. Methods Enzymol. 74, 262-272 (1981). |
| 31. | T. Shimada and S. Nakamura: Cytochrome P-450-mediated activation of procarcinogens and promutagens to DNA-damaging products by measuring expression of umu gene in Salmonella typhimurium TA1535/pSK1002. Biochem. Pharmacol. 36, 1979-1987 (1987)[Medline]. |
| 32. | H. Yamazaki, M. Nakano, Y. Imai, Y. -F. Ueng, F. P. Guengerich, and T. Shimada: Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch. Biochem. Biophys. 325, 174-182 (1996)[Medline]. |
| 33. | H. Yamazaki, Y.-F. Ueng, T. Shimada, and F. P. Guengerich: Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. Biochemistry 34, 8380-8389 (1995)[Medline]. |
| 34. | R. J. Pohl and J. R. Fouts: A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal. Biochem. 107, 150-155 (1980)[Medline]. |
| 35. |
H. Yamazaki,
M. Mimura,
C. Sugahara, and
T. Shimada:
Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7 - and coumarin 7-hydroxylations.
Biochem. Pharmacol.
48,
1524-1527 (1994)[Medline].
|
| 36. | T. Shimada, J. P. Shea, and F. P. Guengerich: A convenient assay for mephenytoin 4-hydroxylase activity of human liver microsomal cytochrome P-450. Anal. Biochem. 147, 174-179 (1985)[Medline]. |
| 37. |
R. G. Knodell,
S. D. Hall,
G. R. Wilkinson, and
F. P. Guengerich:
Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition.
J. Pharmacol. Exp. Ther.
241,
1112-1119 (1987) |
| 38. |
T. Kronbach,
D. Mathys,
J. Gut,
T. Catin, and
U. A. Meyer:
High-performance liquid chromatographic assays for bufuralol 1-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Anal. Biochem.
162,
24-32 (1987)[Medline].
|
| 39. |
T. Omura and
R. Sato:
The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature.
J. Biol. Chem.
239,
2370-2378 (1964) |
| 40. |
K. Mihara and
R. Sato:
Purification and properties of the intact form of NADH-cytochrome b5 reductase from rabbit liver microsomes.
J. Biochem. (Tokyo)
78,
1057-1073 (1975) |
| 41. |
M. Noshiro and
T. Omura:
Immunochemical study on the electron pathway from NADH to cytochrome P-450 of liver microsomes.
J. Biochem. (Tokyo)
83,
61-77 (1978) |
| 42. |
C. H. Williams, Jr. and
H. Kamin:
Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver.
J. Biol. Chem.
237,
587-595 (1962) |
| 43. | F. P. Guengerich, P. Wang, and N. K. Davidson: Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 21, 1698-1706 (1982)[Medline]. |
| 44. |
O. H. Lowry,
N. J. Rosebrough,
A. L. Farr, and
R. J. Randall:
Protein measurement with the Folin phenol reagent.
J. Biol. Chem.
193,
265-275 (1951) |
| 45. | S. L. Wang, J. D. Huang, M. D. Lai, and J. J. Tsai: Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5, 37-42 (1995)[Medline]. |
| 46. | J. A. Goldstein and S. M. F. de Morais: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4, 285-299 (1994)[Medline]. |
| 47. | G. Powis, I. Jardine, R. V. Dyke, R. Weinshilboum, D. Moore, T. Wilke, W. Rhodes, R. Nelson, L. Benson, and C. Szumlanski: Foreign compound metabolism studies with human liver obtained as surgical waste. Relation to donor characteristics and effects of tissue storage. Drug Metab. Dispos. 16, 582-589 (1995)[Abstract]. |
| 48. | P. Skett, C. Tyson, A. Guillouzo, and P. Maier: Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Biochem. Pharmacol. 50, 280-285 (1995)[Medline]. |
| 49. |
H. Sadano and
T. Omura:
Turnover of two drug-inducible forms of microsomal cytochrome P-450 in rat liver.
J. Biochem. (Tokyo)
93,
1375-1383 (1983) |
| 50. | T. Omura: Cytochrome P450 linked mixed function oxidase: turnover of microsomal components and effects of inducers on the turnover of phospholipids, proteins, and specific enzymes. In "Hepatic Cytochrome P-450 Monooxygenase System" (J. B. Schenkman and D. Kupfer, eds.), pp. 295-305. Pergamon Press, Oxford, 1982. |
| 51. | R. E. Pearce, C. J. McIntyre, A. Madan, U. Sanzgiri, A. J. Draper, P. L. Bullock, D. C. Cook, L. A. Burton, J. Latham, C. Nevins, and A. Parkinson: Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch. Biochem. Biophys. 331, 145-169 (1996)[Medline]. |
This article has been cited by other articles:
|
|
 |
|
  Z. E. Barter, J. E. Chowdry, J. R. Harlow, J. E. Snawder, J. C. Lipscomb, and A. Rostami-Hodjegan Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling Drug Metab. Dispos., December 1, 2008; 36(12): 2405 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. van Liempd, J. Kool, W. M. A. Niessen, D. E. van Elswijk, H. Irth, and N. P. E. Vermeulen On-line Formation, Separation, and Estrogen Receptor Affinity Screening of Cytochrome P450-Derived Metabolites of Selective Estrogen Receptor Modulators Drug Metab. Dispos., September 1, 2006; 34(9): 1640 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Wong, N. Wu, D. Roccatano, M. Zacharias, and U. Schwaneberg Sensitive Assay for Laboratory Evolution of Hydroxylases toward Aromatic and Heterocyclic Compounds J Biomol Screen, April 1, 2005; 10(3): 246 - 252. [Abstract] [PDF]
|
|
|
|
|
|
S. C. Chen, L. Zhou, X. Ding, and S. S. Mirvish Depentylation of the Rat Esophageal Carcinogen, Methyl-n-pentylnitrosamine, by Microsomes from Various Human and Rat Tissues and by Cytochrome P450 2A3 Drug Metab. Dispos., September 1, 2001; 29(9): 1221 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schwaneberg, C. Otey, P. C. Cirino, E. Farinas, and F. H. Arnold Cost-Effective Whole-Cell Assay for Laboratory Evolution of Hydroxylases in Escherichia coli J Biomol Screen, April 1, 2001; 6(2): 111 - 117. [Abstract] [PDF]
|
|
|
|
|
|
T. Shimada, F. Tsumura, and H. Yamazaki Prediction of Human Liver Microsomal Oxidations of 7-Ethoxycoumarin and Chlorzoxazone with Kinetic Parameters of Recombinant Cytochrome P-450 Enzymes Drug Metab. Dispos., November 1, 1999; 27(11): 1274 - 1280. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Shimada, J. Watanabe, K. Kawajiri, T. R. Sutter, F. P. Guengerich, E. M.J. Gillam, and K. Inoue Catalytic properties of polymorphic human cytochrome P450 1B1 variants Carcinogenesis, August 1, 1999; 20(8): 1607 - 1614. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
/Hind III and 
X174/Hae III, and in
part C and D were a 100 bp DNA ladder that contained 100 bp, 200 bp,
300 bp, 400 bp, 500 bp, etc.